Overview

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Clinical study to determine safety, tolerability, and maximum tolerated dose of BAY1000394 given in 4 week on / 2 week off schedule to patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Bayer